Company Filing History:
2 out of 10 
1 out of 816 
1 out of 3 Years Active: 2013-2015
Title: The Innovative Contributions of Tomohisa Horibe
Introduction
Tomohisa Horibe is a prominent inventor based in Kyoto, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of chimeric peptides. With a total of five patents to his name, Horibe's work focuses on creating effective anticancer agents that target specific receptors on cancer cells.
Latest Patents
Horibe's latest patents include the development of selective anticancer chimeric peptides that bind to the transferrin receptor. This invention aims to provide a substance that can be used as an anticancer agent or drug delivery system (DDS) with intracellular stability. The chimeric peptide targets cancer cells that overexpress the epidermal growth factor receptor (EGFR) and includes a binding peptide sequence along with a lytic peptide sequence. This innovative approach addresses the need for a treatment that minimizes side effects on normal cells while delivering an instantaneous effect.
Another notable patent involves selective anticancer chimeric peptides that bind to the neuropilin receptor. Similar to his previous work, this invention also aims to create a substance usable as an anticancer agent or DDS, ensuring intracellular stability and evading side effects. The development of this chimeric peptide also targets cancer cells overexpressing EGFR, utilizing a binding peptide and a cytotoxic peptide to achieve its objectives.
Career Highlights
Throughout his career, Tomohisa Horibe has worked with various organizations, including Stella Pharma Corporation. His dedication to advancing cancer treatment through innovative peptide technology has positioned him as a key figure in the field.
Collaborations
Horibe has collaborated with notable colleagues such as Koji Kawakami and Masayuki Kohno. Their combined expertise has contributed to the successful development of groundbreaking cancer therapies.
Conclusion
Tomohisa Horibe's contributions to the field of cancer treatment through his innovative chimeric peptides demonstrate his commitment to improving patient outcomes. His work continues to pave the way for advancements in targeted cancer therapies.